ArticlePloS one2025
Preparation, characterization and in vitro evaluation of atorvastatin nanosuspensions.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thermoresponsive Solid Dispersion to Enhance Dissolution Profile of Atorvastatin Calcium: An Industrially Sustainable Alternative to Conventional Approaches.Pharmaceutics · 2026Article
- Formulation and characterization of nano biopesticides via nanosuspension technology and its packaging designs.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poorly water-soluble drugs present a significant challenge for pharmaceutical development, particularly affecting the pharmacokinetics of orally administered drugs due to their poor dissolution. This study aimed to enhance the dissolution of a low water solubility drug atorvastatin using nanosuspension technology. Antisolvent technique was utilized to prepare atorvastatin calcium nanosuspensions. Different stabilizers were used including Cremophor, HPMC, pluronics (F127, F108, and F68), PEG400, PEG600, PEG 1k, PEG8k, PVA, PVP k30, PVP k10, PVP 44k, SLS, sodium alginate, Tween 20, and Tween 80. The prepared nanosuspensions were lyophilized using mannitol or trehalose as a lyoprotectant. Several optimum formulations were obtained. The selected best optimum formulation was 2% pluronic F127, 80 mg mannitol, and 2 min sonication time. It exhibited a mean particle size of 54.5 nm, a zeta potential of -0.809, and 0.141 PDI after reconstitution. The crystalline state of the nanoparticles was evaluated using differential scanning calorimetry (DSC) and X-ray diffraction (XRD). Fourier-transform infrared spectroscopy (FTIR) was used to assess interactions between the drug substance and the additives. In vitro drug release study was conducted for lyophilized nanosuspension in comparison to the innovator product Lipitor® in two different media, 0.05M potassium phosphate buffer pH 6.8 and 0.1N HCL. The XRD analyses indicated that the lyophilized nanosuspension was partially crystalline with some amorphization and this confirmed by DSC. FTIR results suggested that there was a physical interaction between atorvastatin and the additives. The polymer and lyoprotectant successfully preserved and coated the drug nanoparticles. The lyophilized nanosuspension exhibited superior dissolution in 0.1N HCl. However, the innovator was faster in 0.05 M phosphate buffer. In conclusion, successful preparation of lyophilized nanosuspension of atorvastatin calcium was achieved. The current findings revealed that excipient functionality in terms of stabilization, effect on solid state properties, and drug release were critical for development of stable and efficient nanosuspension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.